Dust mite allergy vaccine for ongoing runny nose and asthma
Part of Ear, nose & throat, Immune system & allergy, Lungs & breathing clinical trials.
This Phase 3 study tests Beltavac®, a treatment aimed at dust mite allergies, to see if it can improve persistent nasal allergy symptoms and help people whose asthma is also affected. You may be a good match if you have confirmed dust mite sensitization and ongoing moderate-to-severe symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 12 to 65, and you can sign consent to join the study
- You have ongoing nasal allergy symptoms (moderate or severe) for at least some time
- You have dust mite allergy confirmed by a skin test and a blood IgE test (both must meet specific cutoffs)
- You are not pregnant (negative pregnancy test); and if nursing, you cannot join
- During screening, your combined nasal symptom and medicine score must be at least 1.5
- Your asthma must be not poorly controlled (severe asthma that needed step 5–6 control recently usually excludes you)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a dust-mite allergy extract (“allergy shots”) to see if it safely reduces symptoms from dust-mite–driven hay fever (rhinitis/rhinoconjunctivitis), and possibly asthma symptoms. If you qualify, it may help your immune system tolerate dust mites better over time.
This Phase 3 study tests whether dust-mite allergy treatment (likely allergy shots) can reduce allergy symptoms and improve safety. It focuses on people whose nose/eye allergy is triggered by house dust mites and who may also have controlled asthma.
This trial tests an under-the-tongue tablet for people with dust mite allergies causing moderate to severe nasal symptoms or mild-to-moderate asthma. The goal is to see if it improves symptoms and can replace or reduce the need for allergy medicines.
This trial tests allergy shots for children with dust mite allergies causing rhinitis or asthma. It aims to see if guiding treatment with detailed allergy testing leads to better results.
This trial tests allergy drops placed under the tongue to treat allergic rhinitis caused by house dust mites. It aims to see if the drops can safely reduce symptoms like sneezing and stuffy nose.
This trial tests if allergy shots (allergen-specific immunotherapy) can reduce symptoms of moderate to severe dust mite allergy. You will be in a room that exposes you to dust mites to see how well the treatment works, compared to a placebo.
Hear when a new House Dust Mite Allergy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.